NCT01723202View on ClinicalTrials.gov

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 7, 2012

Primary Completion Date

April 15, 2022

Study Completion Date

April 15, 2022

Conditions
Follicular Thyroid CancerInsular Thyroid CancerPapillary Thyroid CancerRecurrent Thyroid Cancer
Interventions
DRUG

dabrafenib

150 mg orally twice daily given orally

DRUG

trametinib

150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally

Trial Locations (5)

43210

Ohio State University Medical Center, Columbus

60637

University of Chicago Medical Center, Chicago

77030

The University of Texas-MD Anderson Cancer Center, Houston

92093-0698

University of California, San Diego, San Diego

02114

Massachusetts General Hospital, Harvard Medical School, Boston

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Bhavana Konda

OTHER

NCT01723202 - Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer | Biotech Hunter | Biotech Hunter